^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    RenovoGem (gemcitabine with RenovoCath)

    Associations

    News

    Trials
    Company:
    RenovoRx
    Drug class:
    DNA synthesis inhibitor
    Related drugs:
    Associations

    News

    Trials
    over1year
    TIGeR-PaC: Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC (clinicaltrials.gov)
    P3, N=190, Recruiting, RenovoRx | N=320 --> 190 | Trial completion date: Sep 2023 --> Sep 2026 | Trial primary completion date: Sep 2022 --> Jun 2026
    Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    gemcitabine • albumin-bound paclitaxel • RenovoGem (gemcitabine with RenovoCath)